Barrow Robert sold $722K of DFTX

Barrow Robert (Chief Executive Officer) sold 19,023 shares of Definium Therapeutics, Inc. (DFTX) at $37.94 ($0.72M total) on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barrow Robert
Published Sep 5, 2026, 1:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
high confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The transaction is a routine liquidity event with limited market impact.

02

Market read

Insider sale of ~0.7M USD is modest; unlikely to affect stock price materially.

03

What to watch

Potential upcoming clinical data could outweigh insider sale impact.

Relevance 4/10Novelty 5/10Timing: post‑market filing on Sep 4, 2026

Background

Form 4 filings disclose insider transactions; investors monitor for material changes.

Company-level read

Ticker impact

$DFTXNeutralHigh confidence
Context

CEO Barrow Robert sold 19,023 shares for $721,732 via a 10b5‑1 plan, reducing his stake to 1,494,640 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is modest relative to market cap and typical insider transactions.

Market effects

Limited; reflects routine insider liquidity in biotech sector.

None; company is US‑listed with no broader regional effect.

None; isolated to Definium Therapeutics.

Counterpoint

If insider selling signals concerns, some traders may short, but evidence is weak.

Key entities

  • Barrow Robert

    Chief Executive Officer of Definium Therapeutics.

  • Definium Therapeutics, Inc.

    Biotech firm developing therapies; ticker DFTX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT